Revenue from operations in H1 FY22 stood at ₹2,234.4 crore as compared to ₹1,715.7 crore in H1
FY21, witnessing a growth of 30.2% YoY on account of launch of new products and growth in existing
products.
• PBT (profit before tax) in Q2 FY22 was ₹400.7 crore v/s ₹292.6 crore in Q2 FY21, registering a growth
of 36.9% YoY, due to operating leverage benefit and higher capacity utilisation.
• Cash flow from operations for the 6-month period ended 30th September, 2021, stood at ₹235.5
crore.
• Cash conversion cycle increased to 198 days in H1 FY22 as compared to 180 days in H1 FY21 on
account of increase in inventory level.
• Fixed asset turnover ratio increased to 3.4x in H1 FY22 in comparison to 3x in H1 FY21.
FUTURE OUTLOOK
• The company is exploring partnerships to accelerate entry into the Biologics CDMO (contract
development manufacturing organisation) market, which has been growing at a CAGR of 15% over the
last 5 years.
• Leveraging strong knowhow in biologics development and manufacturing of its parent, Fosun Pharma
group, it plans to build capabilities for biologics CDMO solutions.
• It is planning to start manufacturing Sputnik light vaccine from November, 2021, once it gets export
clearance
FY21, witnessing a growth of 30.2% YoY on account of launch of new products and growth in existing
products.
• PBT (profit before tax) in Q2 FY22 was ₹400.7 crore v/s ₹292.6 crore in Q2 FY21, registering a growth
of 36.9% YoY, due to operating leverage benefit and higher capacity utilisation.
• Cash flow from operations for the 6-month period ended 30th September, 2021, stood at ₹235.5
crore.
• Cash conversion cycle increased to 198 days in H1 FY22 as compared to 180 days in H1 FY21 on
account of increase in inventory level.
• Fixed asset turnover ratio increased to 3.4x in H1 FY22 in comparison to 3x in H1 FY21.
FUTURE OUTLOOK
• The company is exploring partnerships to accelerate entry into the Biologics CDMO (contract
development manufacturing organisation) market, which has been growing at a CAGR of 15% over the
last 5 years.
• Leveraging strong knowhow in biologics development and manufacturing of its parent, Fosun Pharma
group, it plans to build capabilities for biologics CDMO solutions.
• It is planning to start manufacturing Sputnik light vaccine from November, 2021, once it gets export
clearance